康力欣胶囊联合化疗治疗晚期非小细胞肺癌的临床研究

目的 研究康力欣胶囊联合化疗治疗晚期非小细胞肺癌的临床疗效及其安全性。方法 将108晚期非小细胞肺癌患者按随机数字表法分为治疗组和对照组，每组54 例，对照组患者予以TP 方案（紫杉醇+ 顺铂）化疗，治疗组患者在该基础上加服康力欣胶囊。两组患者均以21 d 为1 个周期，共治疗4 个周期后，比较两组患者的近期临床疗效、化疗前后血液肿瘤标志物水平及毒副反应发生情况。结果 治疗组血清癌胚抗原的改善程度大于对照组（P < 0.05）；治疗组细胞角蛋白19 的可溶性片段改善程度大于对照组（P < 0.05）；治疗组临床疗效有效率高于对照组（P < 0.05）；治疗组胃肠道反应发生率、白细胞减少发生率及肝肾功能损害发生率均低于对照组（P < 0.05）。结论 康力欣胶囊联合化疗治疗非小细胞肺癌有增效减毒的作用。

Clinical study on Kanglixin Capsules combined with chemotherapyin treatment of advanced non-small cell lung cancer

Objective To observe the clinical efficacy of Kanglixin Capsules combined with chemotherapyin the treatment of non-small cell lung cancer (NSCLC). Methods Totally 108 patients of NSCLC were randomlydivided into two groups including a treatment group and a control group, each had 54 cases. The patients in thetreatment group were given Kanglixin Capsules combined with chemotherapy, and the patients in the control groupwere given chemotherapy alone, 21 d were a course of treatment. After 4 courses, the short-term clinical therapeuticeffect, serum tumor markers before and after chemotherapy, and the incidences of adverse reactions were comparedbetween the two groups. Results After treatment, the improvement of serum CEA level in the treatment group wassignificantly greater than that in the control group (P < 0.05). The improvement of CYFRA21-1 in the treatmentgroup was significantly greater than that in the control group (P < 0.05). The clinical efficiency of the treatment groupwas higher than that of the control group, the difference was statistically significant (P < 0.05). The incidences ofgastrointestinal reaction, leukopenia, and liver and renal function damages in the treatment group were significantlylower than those of the control group (P < 0.05). Conclusions The efficacy and safety of Kanglixin Capsulescombined with chemotherapy are better than chemotherapy alone in the treatment of non-small cell lung cancer.